News
"It’s just this amazing thing when a peer throws the gauntlet down like that,“ the two-time Grammy winner said in reference ...
Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...
Good morning! Here’s everything you need to know, and some things you don't, before the ASX flings open its doors and begins trading today.
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...
What is getting investors excited today? Let's find out. The post Guess which ASX All Ords stock is rocketing 58% on big US ...
Explore DMX's net worth journey, career success, legal issues, and legacy. Discover how the rap icon went from global fame to ...
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomeruloscler ...
It’s been a tricky few months for the ASX health sector, weighed down by global geopolitical tensions, economic uncertainty ...
Andromeda Metals (ASX:ADN) has pulled off a major breakthrough, with lab tests showing it can produce ultra-high purity 4N ...
Alo’s fourth annual “Aloversary” sale is here, which means it’s time to stock up on all your workout gear and athleisure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results